Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
688202 Shanghai Medicilon Inc.
- 28.62
- +0.01+0.03%
Market Closed Apr 24 15:00 CST
3.85BMarket Cap-11.65P/E (TTM)
29.51High28.32Low28.98KlotVolume28.90Open28.61Pre Close83.63MTurnover2.15%Turnover RatioLossP/E (Static)134.67MShares44.8752wk High1.80P/B3.85BFloat Cap23.3052wk Low34.33Limit Up134.67MShs Float407.19Historical High22.89Limit Down4.16%Amplitude23.30Historical Low--Dividend TTM28.86Avg Price15.33KlotAsk--Div YieldTTM100Lot Size12.72KlotBid
Shanghai Medicilon Inc. News
Shanghai Medicilon Inc. (688202.SH): The first share buyback of 0.1582 million shares.
Gelonghui reported on April 22 that Shanghai Medicilon Inc. (688202.SH) announced that on April 22, 2025, the company repurchased 158,194 shares through centralized bidding, which accounted for 0.12% of the company's total share capital. The highest Fill Price was 28.35 yuan per share, the lowest Fill Price was 27.89 yuan per share, and the total transaction amount was 4,456,442.14 yuan (excluding stamp duty, trading commissions, and other transaction fees).
Medici: Medici: 2024 Annual Report Summary
Medici: Medici: Annual Report 2024
Medici: 2024 Annual Report
Medici: 2024 Annual Report Summary
Shanghai Medicilon Inc.'s revenue in 2024 declined by over 20%, with losses further expanding.
① Affected by multiple factors such as the slowdown in investment and financing in the Industry, intensified market competition, and contraction in domestic market demand, Shanghai Medicilon Inc. is expected to continue expanding its losses to 0.331 billion yuan in 2024; ② By region, the domestic market is heavily impacted by the reduction in R&D investment from local pharmaceutical companies and price wars, becoming the main drag on performance; the Overseas market, although maintaining growth, has seen increased costs due to new experimental facility investments, squeezing profit margins.
Shanghai Medicilon Inc. (688202.SH): Net loss of 0.331 billion yuan in 2024.
Glory Financial reported on April 21 that Shanghai Medicilon Inc. (688202.SH) published its 2024 annual report, with company revenue of 1.04 billion yuan, a year-on-year decrease of 24%; the net income attributable to shareholders turned from a loss of 33.21 million yuan in the same period last year to a loss of 0.331 billion yuan; the net income attributable to shareholders excluding non-recurring items changed from a loss of 57.62 million yuan in the same period last year to a loss of 0.348 billion yuan.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Is Shanghai Medicilon (SHSE:688202) A Risky Investment?
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Shanghai Medicilon Inc. (688202.SH): Has not yet repurchased company shares.
Gelonghui, February 28丨Shanghai Medicilon Inc. (688202.SH) announced that as of February 28, 2025, the company has not yet repurchased its shares through the centralized bidding trading method via the Shanghai Stock Exchange system.
Medici: Medici: 2024 Annual Results Report Announcement
Medici: 2024 Annual Results Report Announcement
Shanghai Medicilon Inc. (688202.SH): Net loss of 0.316 billion yuan for the year 2024.
Shanghai Medicilon Inc. (688202.SH) released its performance report for the year 2024, during the reporting period the company achieved revenue of 10...
Revenues Not Telling The Story For Shanghai Medicilon Inc. (SHSE:688202) After Shares Rise 32%
Shanghai Medicilon Inc.'s (SHSE:688202) Market Cap Increased by CN¥393m, Insiders Receive a 46% Cut
Medici: 2024 Annual Results Forecast
Shanghai Medicilon Appoints Chair, CFO; Shares Up 4%
It's Down 26% But Shanghai Medicilon Inc. (SHSE:688202) Could Be Riskier Than It Looks
Shanghai Medicilon Inc. (688202.SH): Recently, the prices of laboratory monkeys have stabilized.
On December 20, Gelonghui reported that Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor research session that the prices of experimental monkeys have stabilized. The company has proactively taken various measures to ensure the stability of its supply of experimental animals, particularly experimental monkeys, by enriching procurement channels and deepening cooperation with suppliers of experimental animals, to meet the needs of its operation.
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs